Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $31.14

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been assigned an average recommendation of "Buy" from the seven research firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $31.14.

Several analysts have recently commented on CPRX shares. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an "overweight" rating and a $35.00 target price for the company. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. Finally, Citigroup upped their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, August 9th.

Insider Buying and Selling

In other news, insider Gary Ingenito sold 12,000 shares of the business's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares of the company's stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Molly Harper sold 17,500 shares of the company's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its stake in Catalyst Pharmaceuticals by 4.3% in the 1st quarter. California State Teachers Retirement System now owns 106,357 shares of the biopharmaceutical company's stock worth $1,695,000 after acquiring an additional 4,346 shares during the period. Comerica Bank lifted its position in Catalyst Pharmaceuticals by 9.4% during the first quarter. Comerica Bank now owns 51,157 shares of the biopharmaceutical company's stock worth $815,000 after buying an additional 4,377 shares during the period. Cetera Advisors LLC purchased a new position in Catalyst Pharmaceuticals during the first quarter worth about $401,000. CWM LLC boosted its stake in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 3,549 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Catalyst Pharmaceuticals by 12.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,028 shares of the biopharmaceutical company's stock valued at $279,000 after buying an additional 2,002 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ CPRX traded up $0.32 during mid-day trading on Friday, hitting $22.02. 536,075 shares of the company were exchanged, compared to its average volume of 1,102,031. The stock has a 50 day simple moving average of $21.45 and a 200-day simple moving average of $18.96. Catalyst Pharmaceuticals has a 1-year low of $13.00 and a 1-year high of $24.27. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of 18.66, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.